Company intelligence / Profile preview

Zylem Biosciences

Ownership: Private
Development stage: Other

Overview

Zylem’s lead compound, ZYL‑001, targets the SR-B1 receptor to modulate cholesterol and lipid metabolism while activating the adaptive immune system. The company’s MRMs have shown efficacy in small animal models of cancer and obesity. The technology is currently in early preclinical development for oncology, cardiovascular disease, aging-related indications, and viral infections[2][5][6].

Therapeutic areas: OncologyEndocrinologyOtherDermatologyGastroenterologyCardiovascularInfectious Diseases
Modalities: Metabolic Redox Modulators (MRMs)Lipid Nanoparticles (LNPs)
Industry: Biotech

Drug pipeline

4 assets

MRM-ON1

Preclinical

3 more assets in the full pipeline.

Partnerships

Northwestern University (technology licensing/collaboration)[2][7]Portal Innovations (investor/incubator partnership)[10]

Beyond the preview

Go deeper on Zylem Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zylem Biosciences.